Please login to the form below

Not currently logged in
Email:
Password:

AZ in global AI licence agreement

AstraZeneca has completed a global licensing agreement for Meditrina Pharmaceuticals to use its intellectual property in developing, manufacturing and commercialising combinations of aromatase inhibitors with oestrogen and progestin to treat endometriosis. The terms of the agreement were not disclosed.

AstraZeneca has completed a global licensing agreement for Meditrina Pharmaceuticals to use its intellectual property in developing, manufacturing and commercialising combinations of aromatase inhibitors with oestrogen and progestin to treat endometriosis. The terms of the agreement were not disclosed.

Prior to the deal completing, Meditrina, a drugs company specialising in therapies for disorders of the female reproductive system, was already working on Femathina, an AI compound which the firm is repurposing. It recently completed a phase II trial and is being tested for "several serious women's health conditions", including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding.

Meditrina anticipates developing and marketing "a product" in female healthcare in the US, though the firm said it would consider partnering in order to reach other markets worldwide. 

The AZ deal aims to find new treatments specifically for endometriosis, a condition occurring when endometrial stroma and glands are found outside of their normal location in the uterine cavity. According to estimates, up to 10 per cent of all women can be affected by endometriosis, including up to 87 per cent of women with chronic pelvic pain and up to 40 per cent of those suffering with infertility.

"Meditrina will be pursuing this indication, leveraging the work done to date by AstraZeneca," said executive director of R&D at AZ, John Patterson.

6th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics